Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
3.635
-0.015 (-0.41%)
At close: Jul 19, 2024, 4:00 PM
3.660
+0.025 (0.69%)
Pre-market: Jul 22, 2024, 7:03 AM EDT
Revance Therapeutics Market Cap
Revance Therapeutics has a market cap or net worth of $379.67 million as of July 22, 2024. Its market cap has decreased by -81.22% in one year.
Market Cap
379.67M
Enterprise Value
577.82M
1-Year Change
-81.22%
Ranking
Category
Stock Price
$3.64
Market Cap Chart
Since February 6, 2014, Revance Therapeutics's market cap has decreased from $453.20M to $379.67M, a decrease of -16.22%. That is a compound annual growth rate of -1.68%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jul 19, 2024 | 379.70M | -50.81% |
Dec 29, 2023 | 771.90M | -49.18% |
Dec 30, 2022 | 1.52B | 29.62% |
Dec 31, 2021 | 1.17B | -37.87% |
Dec 31, 2020 | 1.89B | 157.62% |
Dec 31, 2019 | 732.10M | -1.68% |
Dec 31, 2018 | 744.60M | -32.67% |
Dec 29, 2017 | 1.11B | 87.35% |
Dec 30, 2016 | 590.30M | -38.42% |
Dec 31, 2015 | 958.60M | 138.58% |
Dec 31, 2014 | 401.80M | -11.34% |
Feb 6, 2014 | 453.20M | - |
View and export this data all the way back to 2014.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Precigen | 401.35M |
AxoGen | 398.59M |
Lyell Immunopharma | 397.70M |
enGene Holdings | 397.05M |
Organogenesis Holdings | 384.46M |
Sight Sciences | 378.65M |
Tourmaline Bio | 377.26M |
uniQure | 375.77M |